Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
sanofi-aventis (formerly Aventis Pharma AG) is developing ilepatril (AVE-7688), a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, for the potential treatment of hypertension and diabetic nephropathy. Ilepatril is currently in phase IIb/III clinical trials for hypertension and phase II trials for diabetic nephropathy. The company had planned to file for approval for the use of ilepatril for hypertension in 2010. Ilepatril was previously being developed for cardiac failure; however, the compound was not listed on Aventis's 2003 pipeline.
Tabrizchi
Reza
R
Memorial University of Newfoundland, Faculty of Medicine, Division of Biomedical Sciences, St John's, Newfoundland and Labrador A1B 3V6 Canada. rtabrizc@mun.ca
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001808:Blood Vessels / Q000201:enzymology*; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006575:Heterocyclic Compounds, 3-Ring / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010330:Patents as Topic; D011480:Protease Inhibitors / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
C479877:AVE 7688; D000959:Antihypertensive Agents; D006575:Heterocyclic Compounds, 3-Ring; D011480:Protease Inhibitors